A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Description: 

The primary objectives of this study are to: Assess the safety and tolerability, including determination of the maximum tolerated dose (MTD), of oral ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). Determine the pharmacokinetic (PK) parameters of ASP2215.

Study Number: 

PH 251814

Phase: 
1/2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02014558

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.